<i>In vitro</i> release of paclitaxel derivative liposome by paddle membrane binding assay

ZHENG Yuting; HONG Tao; XU Kehui; WEN Minghao; YANG Jixue; WU Mengying; HANG Taijun; SONG Min

doi:10.11665/j.issn.1000-5048.2023041803

Journal of China Pharmaceutical University > 2023 > 54(6): 743-748. > DOI: 10.11665/j.issn.1000-5048.2023041803

ZHENG Yuting, HONG Tao, XU Kehui, WEN Minghao, YANG Jixue, WU Mengying, HANG Taijun, SONG Min. In vitro release of paclitaxel derivative liposome by paddle membrane binding assay[J]. Journal of China Pharmaceutical University, 2023, 54(6): 743-748. DOI: 10.11665/j.issn.1000-5048.2023041803

Citation:

PDF (940 KB)

In vitro release of paclitaxel derivative liposome by paddle membrane binding assay

Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China

More Information

Received Date: April 17, 2023
Revised Date: December 05, 2023

Graphical Abstract

Abstract

Abstract

The in vitro release is an important index to evaluate the quality of liposome formulation.Currently, there is no evaluation method for the in vitro release of liposome in pharmacopoeia of various countries, which leads to the lack of unified standard and safety guarantee for the quality evaluation of liposome formulation.Taking the self-made paclitaxel derivative liposomes as an example, the paddle membrane binding method established by optimizing external release conditions was used to simulate the complete release of paclitaxel derivative drugs in 12 hours under physiological conditions.The results showed that using 0.5% SDS-HEPES as the release medium and a dialysis bag with a molecular weight cutoff of 1 000 kD to release the liposome solution met the requirements and had discrimination ability, providing a reference for the development of drug-loaded liposomes release methods in vitro.
- in vitro release of liposome,
- dialysis method,
- paclitaxel derivative liposome,
- paddle membrane binding assay

FullText(HTML)

References (23)

References

[1]	U.S. Food and Drug Administration. extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations[EB/OL]. (1997-09-01) [2023-03-27] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations.
[2]	Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems[J]. Int J Pharm, 2010, 388(1/2): 287-294.
[3]	Liu Y, Zhang YJ, Wang ZY, et al. Research progress in bioanalysis and pharmacokinetics of liposome nanomedicine[J]. Acta Pharm Sin (药学学报), 2023, 58(4): 834-843.
[4]	Skoczen SL, Snapp KS, Crist RM, et al. Distinguishing pharmacokinetics of marketed nanomedicine formulations using a stable isotope tracer assay[J]. ACS Pharmacol Transl Sci, 2020, 3(3): 547-558.
[5]	Varache M, Ciancone M, Couffin AC. Optimization of a solid-phase extraction procedure for the analysis of drug-loaded lipid nanoparticles and its application to the determination of leakage and release profiles[J]. J Pharm Sci, 2020, 109(8): 2527-2535.
[6]	Xu XM, Khan MA, Burgess DJ. A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes[J]. Int J Pharm, 2012, 426(1/2): 211-218.
[7]	Magar KT, Boafo GF, Li XT, et al. Liposome-based delivery of biological drugs[J]. Chin Chem Lett (中国化学快报), 2022, 33(2): 587-596.
[8]	Wang S, Li WX, Sun KY, et al. Study of release kinetics and degradation thermodynamics of ferric citrate liposomes[J]. Chem Phys Lipids, 2019, 225: 104811.
[9]	Alavi S, Mahjoob MA, Haeri A, et al. Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment[J]. Drug Dev Ind Pharm, 2021, 47(8): 1290-1301.
[10]	Tefas LR, Toma I, Sesarman A, et al. Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer[J]. J Liposome Res, 2023, 33(3): 234-250.
[11]	Wang B, Xu QQ, Zhou CJ, et al. Liposomes co-loaded with ursolic acid and ginsenoside Rg3 in the treatment of hepatocellular carcinoma[J]. Acta Biochim Pol, 2021, 68(4): 711-715.
[12]	Hasan MM, Hamiduzzaman M, Jahan I, et al. Formulation development, characterization and In-vitro evaluation of tamoxifen loaded liposomes[J]. J Pharm Res Int, 2020,32(6): 64-82.
[13]	Shah H, Madni A, Khan MM, et al. pH-responsive liposomes of dioleoyl phosphatidylethanolamine and cholesteryl hemisuccinate for the enhanced anticancer efficacy of cisplatin[J]. Pharmaceutics, 2022, 14(1): 129.
[14]	Khan S, Madni A, Rahim MA, et al. Enhanced in vitro release and permeability of glibenclamide by proliposomes: development, characterization and histopathological evaluation[J]. J Drug Deliv Sci Technol, 2021, 63: 102450.
[15]	Modi S, Anderson BD. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method[J]. Mol Pharm, 2013, 10(8): 3076-3089.
[16]	Dubatouka K, Agabekov V. Preparation and characterization of tissue plasminogen activator-loaded liposomes[J]. Soft Mater, 2022, 20(3): 358-363.
[17]	Wallace SJ, Li J, Nation RL, et al. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology[J]. Drug Deliv Transl Res, 2012, 2(4): 284-292.
[18]	Regenold M, Steigenberger J, Siniscalchi E, et al. Determining critical parameters that influence in vitro performance characteristics of a thermosensitive liposome formulation of vinorelbine[J]. J Control Release, 2020, 328: 551-561.
[19]	O?uzhan Kaya H, Karpuz M, Nur Topkaya S. Electrochemical analysis of liposome-encapsulated colistimethate sodium[J]. Electroanalysis, 2022, 34(7): 1114-1120.
[20]	Yu YB, Huang YD, Feng WQ, et al. NIR-triggered upconversion nanoparticles@thermo-sensitive liposome hybrid theranostic nanoplatform for controlled drug delivery[J]. RSC Adv, 2021, 11(46): 29065-29072.
[21]	Heneweer C, Pe?ate Medina T, Tower R, et al. Acid-sphingomyelinase triggered fluorescently labeled sphingomyelin containing liposomes in tumor diagnosis after radiation-induced stress[J]. Int J Mol Sci, 2021, 22(8): 3864.
[22]	Janas C, Mast MP, Kirsamer L, et al. The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers[J]. Eur J Pharm Biopharm, 2017, 115: 73-83.
[23]	Wallenwein CM, Nova MV, Janas C, et al. A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes[J]. Eur J Pharm Biopharm, 2019, 143: 44-50.

Cited By

Get Citation

PDF

XML

Article views (152) PDF downloads (245)

Turn off MathJax

Article Contents

Abstract

References

In vitro release of paclitaxel derivative liposome by paddle membrane binding assay

Abstract

References

Catalog

Export File

Citation

Format

Content